759 THE EFFICACY AND SAFETY OF GUSELKUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR MAINTENANCE STUDY
David T. Rubin(University of California System), Axel Dignaß(Goethe University Frankfurt), Gary R. Lichtenstein, Shadi Yarandi(Janssen (United States)), Tadakazu Hisamatsu(Kyorin University), Julián Panés(Hospital Clínic de Barcelona), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Brian G. Feagan(Western University), Rebbecca Wilson(Janssen (United States)), Brian Bressler(University of British Columbia), Nicole Shipitofsky(Janssen (United States)), Jessica R. Allegretti(Brigham and Women's Hospital), Kuan‐Hsiang Gary Huang(Janssen (United States)), Matthew Germinaro(Johnson & Johnson (United States)), Hongyan Zhang(Tianjin University), Bruce E. Sands(Icahn School of Medicine at Mount Sinai)
Cited by 14
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k